06:15:44 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Diagnos Inc (3)
Symbol ADK
Shares Issued 68,619,982
Close 2021-09-02 C$ 0.51
Market Cap C$ 34,996,191
Recent Sedar Documents

Diagnos renews CARA telemedicine contract with Optina

2021-09-02 11:45 ET - News Release

Mr. Andre Larente reports

DIAGNOS ANNOUNCES A THREE-YEAR CONTRACT RENEWAL WITH OPTINA DIAGNOSTICS PROVIDING A TELEMEDICINE PLATFORM TO SUPPORT THEIR EARLY DETECTION OF ALZHEIMER'S DISEASE TEST

Diagnos Inc. has renewed a contract to provide its telemedicine platform based on CARA (computer-assisted retina analysis) to Optina Diagnostics for an additional three-year period. Optina uses Diagnos's cloud platform to upload images generated by the Optina-4C hyperspectral camera to be used with Optina's awAIr cerebral amyloid status test (for research use only).

Using the Diagnos CARA cloud platform, Optina's proprietary retinal images are processed, securely stored and available to be shared and reviewed by health care professionals and clinics in various locations around the world. Optina benefits from the high throughput of the Diagnos CARA cloud platform as well as the ease of use of the teleophthalmology platform currently used by doctors and other medical professionals.

"This contract renewal is a testimony of the high quality of our telemedicine platform and the agility of Diagnos's people to adapt its platform to enable the rich data collected with the unique Optina-4C hyperspectral camera. We are proud to contribute to the success of innovative companies like Optina. Their work towards a precise Alzheimer's diagnosis is a service we all wish for our loved ones," said Yves-Stephane Couture, vice-president of sales at Diagnos.

"By working with Diagnos, Optina will continue benefiting from rapid data exchange with eye clinics and physicians. This is a key element to support the development of our retinal deep phenotyping diagnostic platform that enables the creation of new tests," said David Lapointe, president and chief executive officer of Optina.

Optina Diagnostics is a privately held company. For commercial reasons, the value of the contract will remain confidential.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the U.S. Food and Drug Administration (United States), CE (Europe), Cofepris (Mexico), and Saudi Food and Drug Administration (Saudi Arabia).

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.